ABG

Ally Bridge Group Portfolio holdings

AUM $63M
1-Year Est. Return 199.29%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+199.29%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$119M
AUM Growth
+$5.08M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
33
New
Increased
Reduced
Closed

Top Buys

1
+$12.2M
2
+$9.53M
3
+$9.29M
4
SLNO icon
Soleno Therapeutics
SLNO
+$9.17M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$5.37M

Top Sells

1
+$15.2M
2
+$7.37M
3
+$6.18M
4
ELVN icon
Enliven Therapeutics
ELVN
+$5.64M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$4.93M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO icon
1
Soleno Therapeutics
SLNO
$2.02B
$20.4M 17.12%
302,483
+123,664
MDGL icon
2
Madrigal Pharmaceuticals
MDGL
$9.91B
$15M 12.54%
+32,662
ATAI icon
3
AtaiBeckley Inc
ATAI
$1.28B
$12.1M 10.13%
+2,287,005
ASND icon
4
Ascendis Pharma
ASND
$14.5B
$10.2M 8.5%
+51,080
LENZ
5
LENZ Therapeutics
LENZ
$385M
$8.17M 6.84%
175,363
-167,959
TSHA icon
6
Taysha Gene Therapies
TSHA
$1.23B
$6.21M 5.2%
+1,898,112
AMLX icon
7
Amylyx Pharmaceuticals
AMLX
$1.55B
$5.94M 4.98%
+437,391
CMPS
8
Compass Pathways
CMPS
$790M
$5.88M 4.92%
1,026,382
-458,618
EPRX
9
Eupraxia Pharmaceuticals
EPRX
$468M
$5.4M 4.52%
+915,000
MNPR icon
10
Monopar Therapeutics
MNPR
$370M
$5.26M 4.41%
64,455
+29,918
ARQT icon
11
Arcutis Biotherapeutics
ARQT
$2.95B
$4.4M 3.68%
+233,220
DFTX
12
Definium Therapeutics
DFTX
$1.72B
$4.26M 3.57%
361,444
-364,728
TARS icon
13
Tarsus Pharmaceuticals
TARS
$3.18B
$4.21M 3.52%
70,778
-50,404
SLDB icon
14
Solid Biosciences
SLDB
$448M
$3.39M 2.84%
549,182
-174,818
PMN icon
15
ProMIS Neurosciences
PMN
$57.8M
$2.65M 2.22%
249,340
+195,963
AVTX icon
16
Avalo Therapeutics
AVTX
$334M
$2.26M 1.9%
+178,100
TECX
17
Tectonic Therapeutic
TECX
$512M
$2.17M 1.82%
138,595
-25,088
WHWK
18
Whitehawk Therapeutics
WHWK
$156M
$1.55M 1.3%
817,939
CNTA
19
Centessa Pharmaceuticals
CNTA
$3.79B
– –
-293,986
ELVN icon
20
Enliven Therapeutics
ELVN
$1.73B
– –
-281,394
GERN icon
21
Geron
GERN
$919M
– –
-3,251,475
INSM icon
22
Insmed
INSM
$31.2B
– –
-47,710
KRRO icon
23
Korro Bio
KRRO
$102M
– –
-154,223
LXEO icon
24
Lexeo Therapeutics
LXEO
$497M
– –
-867,302
MLTX icon
25
MoonLake Immunotherapeutics
MLTX
$1.3B
– –
0
1
2